Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes, but otherwise healthy~* HbA1c between 6.6% and 9.5%, inclusive.~* Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.~* Treated with a stable dose of metformin for at least 2 months prior to screening.~Exclusion Criteria:~* Patients previously in a study using exenatide.~* Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).~* Treated with insulin within 3 months of screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Arm (Type: EXPERIMENTAL): Exenatide and Metformin
- Insulin Glargine Arm (Type: ACTIVE_COMPARATOR): Insulin Glargine and Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).